{"id":35099,"date":"2025-06-12T15:00:44","date_gmt":"2025-06-12T07:00:44","guid":{"rendered":"https:\/\/flcube.com\/?p=35099"},"modified":"2025-06-12T15:00:44","modified_gmt":"2025-06-12T07:00:44","slug":"novo-nordisk-china-restructures-to-form-new-obesity-and-diabetes-department","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=35099","title":{"rendered":"Novo Nordisk China Restructures to Form New Obesity and Diabetes Department"},"content":{"rendered":"\n<p>Danish pharmaceutical giant Novo Nordisk&#8217;s (<a href=\"https:\/\/www.google.com\/finance\/quote\/NVO:NYSE\">NYSE: NVO<\/a>) China unit announced an organizational restructuring, merging its Obesity Business Unit into the Diabetes Business Department (DBD) to form a new Obesity &amp; Diabetes Business Department (DOD). Zhang Hui, Corporate Vice President of Novo Nordisk China&#8217;s Diabetes Business Department, will oversee sales management for the new department.<\/p>\n\n\n\n<p><strong>New Responsibilities<\/strong><br>Effective July 1, Novo Nordisk&#8217;s existing insulin sales team will also take on responsibility for promoting the obesity product Wegovy (semaglutide).<\/p>\n\n\n\n<p><strong>Leadership Changes<\/strong><br>Zhang Yifan, former Vice President of Novo Nordisk&#8217;s Obesity Business Unit, will depart on June 30 to assume the role of General Manager for Lundbeck China (Mainland &amp; Hong Kong). The position had been vacant since the departure of former Lundbeck China GM Jens Hoeyer, with interim leadership provided by Yang Shaohua, Vice President of Strategic Finance, Commercial &amp; Partnerships at Lundbeck China. Upon Zhang Yifan&#8217;s appointment, Yang Shaohua will continue in his current role.<\/p>\n\n\n\n<p><strong>Background on Zhang Yifan<\/strong><br>Zhang Yifan began his career as a management trainee at Novo Nordisk&#8217;s global headquarters. In 2023, he was transferred to Novo Nordisk China, where he established and led the obesity business unit, driving the launch of Wegovy in China. Concurrently, he served as National Sales Head for Novo Nordisk China&#8217;s GLP-1 diabetes business, overseeing commercialization of the diabetes brands Ozempic and Xultophy.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Danish pharmaceutical giant Novo Nordisk&#8217;s (NYSE: NVO) China unit announced an organizational restructuring, merging its&#8230;<\/p>\n","protected":false},"author":1,"featured_media":35102,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7],"tags":[39,148,86],"class_list":["post-35099","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","tag-diabetes","tag-novo-nordisk","tag-obesity"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Novo Nordisk China Restructures to Form New Obesity and Diabetes Department - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Danish pharmaceutical giant Novo Nordisk&#039;s (NYSE: NVO) China unit announced an organizational restructuring, merging its Obesity Business Unit into the Diabetes Business Department (DBD) to form a new Obesity &amp; Diabetes Business Department (DOD). Zhang Hui, Corporate Vice President of Novo Nordisk China&#039;s Diabetes Business Department, will oversee sales management for the new department.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=35099\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Novo Nordisk China Restructures to Form New Obesity and Diabetes Department\" \/>\n<meta property=\"og:description\" content=\"Danish pharmaceutical giant Novo Nordisk&#039;s (NYSE: NVO) China unit announced an organizational restructuring, merging its Obesity Business Unit into the Diabetes Business Department (DBD) to form a new Obesity &amp; Diabetes Business Department (DOD). Zhang Hui, Corporate Vice President of Novo Nordisk China&#039;s Diabetes Business Department, will oversee sales management for the new department.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=35099\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-06-12T07:00:44+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/1205.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35099#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35099\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Novo Nordisk China Restructures to Form New Obesity and Diabetes Department\",\"datePublished\":\"2025-06-12T07:00:44+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35099\"},\"wordCount\":239,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35099#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/1205.webp\",\"keywords\":[\"Diabetes\",\"Novo Nordisk\",\"Obesity\"],\"articleSection\":[\"Company\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=35099#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35099\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=35099\",\"name\":\"Novo Nordisk China Restructures to Form New Obesity and Diabetes Department - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35099#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35099#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/1205.webp\",\"datePublished\":\"2025-06-12T07:00:44+00:00\",\"description\":\"Danish pharmaceutical giant Novo Nordisk's (NYSE: NVO) China unit announced an organizational restructuring, merging its Obesity Business Unit into the Diabetes Business Department (DBD) to form a new Obesity & Diabetes Business Department (DOD). Zhang Hui, Corporate Vice President of Novo Nordisk China's Diabetes Business Department, will oversee sales management for the new department.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35099#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=35099\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35099#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/1205.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/1205.webp\",\"width\":1080,\"height\":608,\"caption\":\"Novo Nordisk China Restructures to Form New Obesity and Diabetes Department\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=35099#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Novo Nordisk China Restructures to Form New Obesity and Diabetes Department\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Novo Nordisk China Restructures to Form New Obesity and Diabetes Department - Insight, China&#039;s Pharmaceutical Industry","description":"Danish pharmaceutical giant Novo Nordisk's (NYSE: NVO) China unit announced an organizational restructuring, merging its Obesity Business Unit into the Diabetes Business Department (DBD) to form a new Obesity & Diabetes Business Department (DOD). Zhang Hui, Corporate Vice President of Novo Nordisk China's Diabetes Business Department, will oversee sales management for the new department.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=35099","og_locale":"en_US","og_type":"article","og_title":"Novo Nordisk China Restructures to Form New Obesity and Diabetes Department","og_description":"Danish pharmaceutical giant Novo Nordisk's (NYSE: NVO) China unit announced an organizational restructuring, merging its Obesity Business Unit into the Diabetes Business Department (DBD) to form a new Obesity & Diabetes Business Department (DOD). Zhang Hui, Corporate Vice President of Novo Nordisk China's Diabetes Business Department, will oversee sales management for the new department.","og_url":"https:\/\/flcube.com\/?p=35099","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-06-12T07:00:44+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/1205.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=35099#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=35099"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Novo Nordisk China Restructures to Form New Obesity and Diabetes Department","datePublished":"2025-06-12T07:00:44+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=35099"},"wordCount":239,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=35099#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/1205.webp","keywords":["Diabetes","Novo Nordisk","Obesity"],"articleSection":["Company"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=35099#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=35099","url":"https:\/\/flcube.com\/?p=35099","name":"Novo Nordisk China Restructures to Form New Obesity and Diabetes Department - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=35099#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=35099#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/1205.webp","datePublished":"2025-06-12T07:00:44+00:00","description":"Danish pharmaceutical giant Novo Nordisk's (NYSE: NVO) China unit announced an organizational restructuring, merging its Obesity Business Unit into the Diabetes Business Department (DBD) to form a new Obesity & Diabetes Business Department (DOD). Zhang Hui, Corporate Vice President of Novo Nordisk China's Diabetes Business Department, will oversee sales management for the new department.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=35099#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=35099"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=35099#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/1205.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/1205.webp","width":1080,"height":608,"caption":"Novo Nordisk China Restructures to Form New Obesity and Diabetes Department"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=35099#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Novo Nordisk China Restructures to Form New Obesity and Diabetes Department"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/1205.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/35099","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=35099"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/35099\/revisions"}],"predecessor-version":[{"id":35103,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/35099\/revisions\/35103"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/35102"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=35099"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=35099"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=35099"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}